SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
Hormone therapies have played a major role in improving survival for patients with ER+ breast cancer [1]. By blocking or reducing estrogen’s impact, these treatments slow the cancer’s growth and help ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors Overall, 262 patients with ER+/HER2– ...
The modulation of colorectal cancer (CRC) by oestrogen receptors has emerged as a field of great promise, drawing attention to the differential roles of receptor subtypes in tumour initiation, ...
Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
Researchers have investigated the role that estrogen plays in signaling more gut pain, and it isn't working alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback